Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR2554 Alone or with SHR3680 in mCRPC
NCT03741712Phase 2Terminated
- Sponsor
- Hengrui
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zeprumetostat in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Hengrui. Primary endpoints: Dose-Limiting Tolerance at 12 months, Maximum-Tolerated Dose at 12 months and 1 more. Started Nov 2018; status: terminated.
02
Drugs
zeprumetostat
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03741712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03741712.